Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5652
Abstract: Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a randomized… read more here.
Keywords: dose nab; previously treated; nab paclitaxel; phase trial ... See more keywords